Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine

Journal of Clinical Oncology

Volumn 19, Issue 8, 2001, Pages 2293-2301

  Evans, W E ^a   Yuen Yi Hon, ^a   Bomgaars, L ^a   Coutre, S ^a   Holdsworth, M ^a   Janco, R ^a   Kalwinsky, D ^a   Keller, F ^a   Khatib, Z ^a   Margolin, J ^a   Murray, J ^a   Quinn, J ^a   Ravindranath, Y ^a   Ritchey, K ^a   Roberts, W ^a   Rogers, Z R ^a   Schiff, D ^a   Steuber, C ^a   Tucci, F ^a   Kornegay, N ^a   Krynetski, E Y ^a   Relling, M V ^a   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; CHILD; DRUG INDUCED DISEASE; DRUG TOXICITY; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME METABOLISM; FEMALE; GENOTYPE; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER TOXICITY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOCYTE TRANSFUSION;

EID: 0035871560     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.8.2293     Document Type: Article

References (39)

1. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity
2. Pharmacogenetics of cancer therapy: Getting personal
3. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia
4. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase
5. Thiopurine S-methyltransferase deficiency: Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians
6. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance
7. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms
8. Polymorphism of the thiopurine S-methyltransferase gene in African Americans
9. Thiopurine methyltransferase alleles in British and Ghanaian populations
10. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine
11. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population
12. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): Mechanisms for the genetic polymorphism of TPMT activity
13. Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: Mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C
14. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations
15. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia
16. Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase
17. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus
18. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
19. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia
20. Childhood leukaemia: A relationship between intracellular 6-mercaptopurine metabolites and neutropenia
21. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia
22. Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis
23. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient
24. Thiopurine-methyltransferase activity to assess azathioprine myelotoxicity in renal transplant recipients
25. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia
26. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient
27. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells
28. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis
29. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia
30. Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations
31. Clinical studies of 6-methylmercaptopurine riboside (NSC-40774) in acute leukemia
32. Studies of combination 6-mercaptopurine (NSC-755) and 6-methylmercaptopurine riboside (NSC-40774) in patients with acute leukemia and metastatic cancer
33. Combination 6-mercaptopurine and 6-methylmercaptopurine riboside in the treatment of adult acute leukemia: A Southwest Oncology Group study
34. Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: Pharmacokinetic characteristics
35. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia
36. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia
37. High incidence of secondary brain tumors related to irradiation and antimetabolite therapy
38. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia
39. Pharmacogenomics: Translating functional genomics into rational therapeutics